CATX
Perspective Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Perspective Therapeutics entered a clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 with Keytruda in FAP-alpha-positive solid tumorsSep 14, 2026
- Perspective Therapeutics receives European orphan drug designation for [212Pb]VMT-α-NET in GEP-NETsJul 28, 2026
- Perspective Therapeutics expanded its therapeutic focus areas and dosed the first patient with [212Pb]VMT-α-NET in a meningioma cohortJun 3, 2026
- Perspective Therapeutics dosed the first patients in new cohorts of two ongoing Phase 1/2a studiesMay 18, 2026
- Perspective Therapeutics announces first patient dosed with PSV359 in second cohort of Phase 1/2a study in patients with FAP-α positive solid tumorsOct 2, 2025